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Abstract
Introduction. A mild therapeutic hypothermia (MTH) is a promising adjunct treatment in patients suffering from cardiac 
arrest.
Material and methods. In 2012–2013 a 13 out of 216 consecutive patients admitted due to cardiac arrest were quali-
fied to MTH. Cooling was started at the admission with the intravenous infusion of saline at a degree of 4°C, then 
continued with intravascular automated cooling system.
Results. The study group consisted of five women and eight men (mean age 59 years). The most common mechanism 
of cardiac arrest was ventricular fibrillation or ventricular tachycardia due to acute myocardial infarction (92.3%). The 
mean time of return of spontaneous circulation (ROSC) was 15 min 54 s. The mean time from cardiac arrest to the 
start of the cooling was 1h 10 min. During MTH an increase in white blood cell count and serum level of amylase and 
CRP was observed. The in-hospital mortality was 7/13 patients (53.8%). Patients who survived were younger (53.8 vs. 
63.6 years), had lower incidence of coronary artery disease and ventricular fibrillation was the mechanism of cardiac 
arrest. In addition, patients who survived had prolonged time to ROSC (median time 19 min vs. 13 min) and reduced 
time: to the start of cold saline infusion (median time 58 min vs. 85 min), from cardiac arrest to the beginning of the 
intravascular cooling (median time 3 h 20 min vs. 3 h 50 min) and hospital stay (median time 471 h vs. 1232 h) in 
comparison with patients with fatal outcome. Five patients were discharged from the hospital in a good neurological 
condition (4 patients — 0 points and 1 patient — 1 point in Rankin scale).
Conclusions. All the patients who survived and were treated with MTH, were discharged in a good neurological condition. 
The implementation of endovascular cooling device greatly improves precise temperature control in patients undergoing 
MTH.
Key words: mild therapeutic hypothermia, cardiac arrest, acute coronary syndrome
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 — systolic blood pressure > 80 mm Hg without inotropic 
and vasopressor support.
The exclusion criteria consisted of:
 — body temperature measured in urine bladder < 30°C
 — advanced concomitant diseases indicating reduced life 
expectancy (end-stage kidney failure, chronic respira-
tory failure requiring oxygen therapy, end-stage heart 
failure, advanced neoplasm, severe hepatic diseases);
 — active bleeding;
 — any known congenital and acquired bleeding disorder 
(excl. patients who used anticoagulant agents);
 — pregnancy;
 — hypoglycemia (glucose < 50 mg/dl);
 — other disorders of consciousness.
MHT management
All the patients were mechanically ventilated via endotra-
cheal tube with intermittent positive pressure ventilation 
(IPPV). Cooling was initiated with an intravenous infusion 
of saline at a degree of 4°C. The rate of administration 
was different among the study group. Sometimes maximal 
rate of infusion was implemented whereas in other cases 
saline was injected. A temperature sensor was placed in 
urine bladder in order to monitor body temperature. All 
the patients had coronary angiography and percutaneo-
us coronary intervention (PCI), if necessary. In order to 
perform an intravascular cooling, a triple lumen catheter 
(diameter 9.3 F and length: 38 or 45 mm) (ICY Intervascular 
Heat Exchange Kit ZOLL Medical Corp.) was placed in the 
inferior vena cava via femoral vein shortly after the end of 
coronary intervention. Cooling was continued on the ward 
at a maximum rate using intravascular control unit Thermo-
gard XP (ZOLL Medical Corp.). After reaching temperature 
target level at 33°C the patients were maintained in mild 
hypothermia for 36 hours [12]. After 36h patients were 
gradually re-warmed at a rate of 0.1°C/h to reach 36.5°C 
and then had their body temperature closely monitored. 
The intravascular control unit was not used longer than 
5 days in each patient. 
Concomitant therapy
On admission all the patients were administered loading 
dose of 2 antiplatelet agents (300 mg of acetylsalicylic 
acid and 600 mg of clopidogrel), 5000 IU of unfractionated 
heparin, proton pomp inhibitor and antibiotic (cefuroxime 
1.5 g IV every 8 hours), sedatives (midazolam or propofol) 
and muscle relaxants (atracurium or pipecuronium). The 
type of analgosedation used was dependant on the acces-
sibility of agents and doctor’s on call preferences. During 
MTH 2 of the following antiplatelet agents were adminis-
tered at maintenance doses (75 mg QD of acetylsalicylic 
acid, 75 mg QD of clopidogrel or 90 mg BID of ticagrelor 
depending on the type of agent used before PCI), proton 
pomp inhibitor (40 mg q.d. of pantoprazole), antibiotic 
Introduction
Cardiac arrest due to cardiovascular diseases is one of 
the most common cause of death in developed countries. 
In cardiac intensive care units in Europe there are over 
275 000 patients treated due to out-of-hospital cardiac ar-
rest (OHCA). Around 25% of those patients are young, aged 
< 65years. Despite intensive treatment only less than 10% 
of patients are discharged home, whereas their annual mor-
tality is estimated at 50% [1, 2]. The main cause of death in 
patients after successful cardiopulmonary resuscitation is 
post-ischemic central nervous system (CNS) injury. A mild 
therapeutic hypothermia (MHT) is a promising treatment 
method which may improve prognosis in above-mentioned 
patients [1, 2]. The method goal is to cool a patient to 
a target temperature of 32–34°C, maintain this tempera-
ture for 12–24 h and then gradually re-warm patient to 
normothermia. It can be achieved by using ice bags, cool-
ing blankets, cold crystalloids intravenous infusion and 
intravascular automated cooling systems [3]. MHT was 
demonstrated to exert multi-directional neuroprotective 
effects. Due to neural cell structural integrity maintenance, 
inhibition of apoptosis and favorable impact on CNS cells 
metabolism it slows down set of events which account for 
post-ischemic brain injury [4].
Based on International Liaison Committee on Resusci-
tation (ILCOR) and European Resuscitation Council (ERC) 
guidelines, MHT has been recommended in adults after 
OHCA due to ventricular fibrillation (VF) with the return of 
spontaneous circulation (ROSC) [5, 6]. MHT is also recom-
mended in patients after cardiac arrest due to mechanism 
other than ventricular fibrillation and after in-hospital car-
diac arrest [1, 5]. MTH is also applied in patients suffering 
from traumatic CNS or spinal cord injury, stroke and acute 
liver failure [7–11]. MTH as a novel and invasive method 
of treatment that has some adverse effects may still rise 
concerns. Therefore its use may initially be regarded as 
controversial. The aim of this study was to present our 
experience concerning MTH implementation in patients 
after cardiac arrest admitted to Cardiac Intensive Care Unit 
(CICU) of Voivodeship Hospital in Kielce, Poland.
Materials and methods
Eligibility assessment to MTH
Procedure implementation and patients’ qualification to 
MTH was based on experience from other scientific centres 
[12]. We used the following inclusion criteria:
 — age > 18 years;
 — out-of-hospital cardiac arrest due to ventricular fibril-
lation, pulseless ventricular tachycardia, asystole or 
pulseless electrical activity (PEA);
 — time from cardiac arrest < 4 h;
 — 8 or less points in Glasgow Coma Scale (GCS);
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(the dose was adjusted to kidney function), sedatives and 
muscle relaxants in continuous intravenous infusion. 
Some patients also required fentanyl administration. All 
the patients were given low molecular weight heparin as 
a prophylaxis of thromboembolic complications, atorvas-
tatin 80 mg QD; amantadine 200 mg QD and furosemide 
20 mg QD. In order to determine the amount and type of 
replaced fluids a diuresis, central venous pressure and 
blood pressure was analysed. Inotropic agents (dobuta-
mine, dopamine) and vasopressor (norepinephrine) were 
applied depending on the hemodynamic state of each 
patient. After reaching body temperature of 36.0°C the 
muscle relaxants and then sedatives were discontinued. 
Parenteral and oral nutrition of patients was started at day 
4–5 after normothermia was achieved.
Patient monitoring
During MTH the following parameters were monitored in 
patients:
 — body temperature assessed by urine bladder sensor;
 — pulse;
 — blood pressure measured invasively;
 — central venous pressure;
 — cardiac output (CO) measured invasively by using Vigileo 
(Edwards Lifesciences);
 — oxygen saturation (SaO2);
 — a complete blood count, transferase and amylase 
activity; creatinine, creatinine kinase, and its cardiac 
isoenzyme levels; sodium, potassium, magnesium, glu-
cose, C-reactive protein (CRP), brain natriuretic peptide 
(BNP), lipid profile, partial thromboplastin time (aPTT), 
international normalized ratio (INR), D-dimer values 
and arterial blood gas.
Electrocardiogram and echocardiography were perfor-
med on admission, during next days of hospitalization and 
in case of deteriorating state of patients. Neurological state 
was assessed using Rankin scale (0 — no symptoms, 1 — no 
significant disability, despite some symptoms, 2 — slight 
disability, 3 — moderate disability, 4 — moderately severe 
disability, 5 — severe disability) before patient’s discharge 
from hospital [13].
Results
Between 1 January 2012 and 31 December 2013, 216 
patients were hospitalized in CICU due to cardiac arrest. 
A severe heart failure, respiratory tract diseases, gastro-
intestinal bleeding, neurological disorders, intoxication, 
CNS injury were the cause of cardiac arrest in 155 patients 
(71.76%). In the other 61 patients (28.84%) the main cause 
of cardiac arrest was acute coronary syndrome (Fig. 1). 
From the latter group only 13 patients were qualified 
to MTH (21.3%). Patients did not fulfill eligibility criteria 
when the following occurred: more than 8 points in GCS, 
hemodynamic instability requiring catecholamines, severe 
concomitant diseases with reduced life expectancy, in-
-hospital cardiac arrest and if the decision of doctor-on-call 
was negative. Despite the exclusion criteria, 2 patients after 
in-hospital cardiac arrest were qualified do MTH because 
we believed it could have improved their prognosis. The 
study group consisted of 5 women and 8 men. The mean 
age of patients was 59 years (59.8 years in women and 
58.6 years in men). The most common cause of cardiac 
arrest was malignant ventricular arrhythmia (ventricular 
fibrillation or ventricular tachycardia). In more than half of 
the cases the cardiac arrest happened in the presence of 
medical staff. In all cases cardiac arrest was observed in 
the presence of a witness who initiated CPR and suspec-
ted acute coronary syndrome as a cause of the event. The 
final diagnosis of myocardial infarction was confirmed in 
12/13 patients: 7/13 patients had ST-segment elevation 
myocardial infarction (STEMI) while in 5/13 a non-ST 
segment elevation myocardial infarction (NSTEMI) was 
observed (Table 1). The median time to ROSC was 18 min. 
After excluding 2 patients with CPR over 1 h, the median 
time for the study group reduced to 17 min. The median 
time from cardiac arrest to initial intravenous cooling with 
a cold saline infusion was 1h and median time from admis-
sion to the ward: 15 min. Median time from cardiac arrest 
to initial intravascular cooling was 3 h 40 min. The target 
body temperature of 33°C was achieved after 3 h 50 min 
(median time) from the beginning of the procedure and 
after 7 h 30 min from the cardiac arrest (median time). Me-
dian time from the cardiac arrest to complete re-warming of 
patients with body temperature of 36.5°C was 75 h 22 min. 
Median time from the beginning to the end of cooling was 
30 h. Median time of intravascular control unit functioning 
after reaching target body temperature of 36.5°C was 21 h. 
Median time in patients from cardiac arrest to regaining of 
OHCA 
216
Other than ACS 
155 (71.8%)
ACS 
61 (28.2%) 
Survived 
6 (46.2%) 
Survived 
21 (43.7%) 
Survived 
81 (52.3%)
Died 7 
(53.8%) 
Died 27 
(56.3%) 
Died 74 
(47.7%)
MTH 
13 (21.3%) 
Others 
48 (78.7%)
Figure 1. Patients after cardiac arrest hospitalized at the time 
of therapeutic hypothermia recruitment; OHCA — out-of hospital 
cardiac arrest, ACS — acute coronary syndrome, MTH — mild the-
rapeutic hypothermia
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consciousness was 130 h. Median time from cardiac arrest 
to patient’s discharge from hospital was 574 days, that is 
24 days (Table 2). The mean body temperature of patients 
on admission was 36.3°C. Ten patients were qualified to 
PCI, in 2 cases we observed disseminated atherosclerotic 
lesions in coronary arteries that required qualification to 
CABG. In one patient no atherosclerotic lesions in coronary 
arteries were noted. During MHT an increase in white blood 
count, amylase activity and C-reactive protein was observed 
while hemoglobin level, heart rate and diastolic blood 
pressure decreased. No changes in other parameters were 
noted (Table 3, Figure 2). During MHT patients required 
increased amount of fluids infusion and temporary use of 
catecholamines (Table 4). Among the adverse effects the 
following were observed: malignant ventricular arrhythmias 
(23.1%), upper gastrointestinal bleeding (7.7%), acute stent 
thrombosis (7.7%), acute kidney failure (7.7%), acute lower 
limb ischaemia (7.7%). After the end of hypothermia pneu-
monia (30.8%), sepsis (7.7%) and upper gastrointestinal 
bleeding (7.7%) occurred. The in-hospital mortality in the 
study group was 53.8%. In group of patients with fatal 
outcome we observed a death during cooling due to acute 
lower limb ischaemia (procedure-related complication) and 
respiratory failure requiring prolonged mechanical ventila-
tion (68 days). Four patients did not regain consciousness. 
The in-hospital mortality in patients after cardiac arrest due 
to acute coronary syndrome that were not qualified to MTH 
was 56% while in the group with other typical comorbidities 
the mortality rate was 47.7%. Among the 6 MTH patients 
who survived, 5 were discharged from hospital without any 
neurological disorder (0 pts in 4 patients, 1 pt in 1 patient 
in Rankin scale) and one patient was transferred to neuro-
logical rehabilitation centre (3 pts in Rankin scale). In the 
group of patients who survived the following parameters 
Table 1. Clinical characteristics
Variable All the patients 
n = 13
Patients who survived 
n = 6
Patients who died 
n = 7
Mean age, years 59.1 53.8 63.6
Sex:
• female 5 (38.5%) 2 (33.3%) 3 (42.8%)
• male 8 (61.5%) 4 (66.7%) 4 (57.1%)
Location of cardiac arrest:
• home 6 (46.1%) 3 (50%) 3 (42,9%)
• hospital/out-patient clinic 5 (38.5%) 1 (16.7%) 4 (47.1%)
• ambulance 2 (15.4%) 2 (33.3%) 0
Cardiac arrest mechanism:
• VF 11 (84.6%) 6 (100%) 5 (71.4%)
• asystole 2 (15.4%) 0 2 (28.6%)
Primary cause:
• myocardial infarction 12 (92.3%) 6 (100%) 6 (85.7%)
• other 1 (7.7%) 0 1 (14.3%)
Type of ACS:
• STEMI 7 (53.8%) 4 (66.7%) 3 (42.9%)
• NSTEMI 5 (38.5%) 2 (33.3%) 3 (42.9%)
Concomitant diseases:
• CAD 6 (46.1%) 2 (33.3%) 4 (47.1%)
• HTN 8 (61.5%) 3 (50%) 5 (71.4%)
• CKD 1 (7.7%) 1 (16.7%) 0
• DM 2 (15.4%) 1 (16.7%) 1 (14.3%)
• stroke in anamnesis 2 (15.4%) 1 (16.7%) 1 (14.3%)
• alcoholism 4 (30.8%) 3 (50%) 1 (14.3%)
• narcotics 1 (7.7%) 1 (16.7%) 0
VF — ventricular tachycardia; ACS — acute coronary syndrome; STEMI — myocardial infarction with ST segment elevation; NSTEMI — myocardial infarction without ST segment elevation; CAD — coronary artery 
disease; HTN — hypertension; CKD — chronic kidney disease; DM — diabetes mellitus
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Table 2. Mean and median time (hours: minutes) from cardiac arrest to next stages of treatment
Stage of treatment All the patients 
n = 13
Patients who survive 
n = 6
Patients who died 
n = 7
ROSC
Mean 00:24 00:27 00:21
Median time 00:18 00:19 00:13
Cooling initiation
Mean 01:11 01:00 01:20
Median time 01:00 00:58 01:25
Hypothermia catheter
Mean 03:40 03:20 03:57
Median time 03:40 03:20 03:50
Target body temperature of 33°C
Mean 07:30 05:50 08:50
Median time 07:30 05:00 08:22
Hypothermia catheter removal
Mean 110:51 100:36 120:07
Median time 113:57 105:15 121:00
Regaining of consciousness
Mean 228:00 173:00 391:00*
Median time 130:25 130:25 391:00*
Return of spontaneous breathing
Mean 450:46 301:00 1345:00**
Median time 259:05 136:10 –
Discharge from hospital
Mean 870:00 666:00 1047:00
Median time 574:36 471:24 1232:25
*2 patients; **1 patient; ROSC — return of spontaneous circulation
Table 3. Mean values of chosen variables in consecutive stages 
of hypothermia
Variable 1st day 2nd day 3rd day
HR [min–1] 95 78 83
MAP [mm Hg] 90.6 88.6 88.5
Mean diuresis [mL] 3009 3734 2309
Hgb [g/L] 146 142 115
Hct 0.44 0.42 0.34
PLT [109/L] 221 186 152
White blood count 
[109/L]
15.0 15.4 13.0
CRP [mg/L]* 19.5 81.2 124.7
Amylase [U/L]** 114 385 217
Creatinine [mg/dL] 1.3 1.35 1.33***
Potassium [mmol/L] 4.12 4.38 4.53
pH 7.2 7.3 7.4
*Amylase — upper limit 108 U/L; **CRP — upper limit 5 mg/L; ***after excluding patient with 
acute kidney failure; HR — heart rate; MAP — mean arterial pressure; Hgb — hemoglobin; Hct — 
hematocrit; PLT — platelets; CRP — C-reactive protein
were observed: younger age (53.8 vs. 63.6 years), lower 
incidence of coronary artery disease, more frequent ventri-
cular fibrillation as a cause of cardiac arrest, longer time to 
ROSC (median time: 19 vs. 13 min), reduced time to initial 
cold saline infusion (median time 58 vs. 85 min), reduced 
time from cardiac arrest to intravascular cooling (median 
time 3 h 20 min vs. 3h 50 min) and reduced hospital stay 
(median time 471 vs. 1232 h).
Discussion
Therapeutic hypothermia has become a matter of an inte-
rest among clinicians since the publication of guidelines 
based on multicenter randomized clinical trials [14, 15]. 
Undoubtedly this attitude is associated with MTH favourable 
impact on prognosis in patient after OHCA [14–17]. MTH is 
a novel method and therefore its use and implementation 
provides many observations and sometimes contradic-
tory conclusions that enrich our knowledge. Based on our 
preliminary experience with MTH, it has to be stated that 
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despite its easy implementation associated with automated 
cooling technology, MTH still requires multidisciplinary ap-
proach to patients. There are often many doubts whether 
to qualify patient or not. The decision about cooling should 
be made quickly and as early as possible. The decision is 
not always easy bearing in mind that physician has to do 
it alone, on a night shift, often not having enough data 
concerning patient’s condition. If patient has normal re-
flexes and motor response and medical aid was provided 
shortly after cardiac arrest occurred there is a chance 
that he/she will quickly regain consciousness and good 
neurological status after the treatment. Unfortunately such 
scenario do not happen in all patients after cardiac arrest. 
Perhaps implementation of hypothermia in this group would 
improve the rate of successful therapy. After analyzing the 
study data we found that 8 patients who might have been 
potential candidates for MTH were not qualified to the pro-
cedure due to doctor’s on call decision. It happened during 
Figure 2. Significant deviations in laboratory tests in consecutive days of hypothermia; CRP — C-reactive protein; Leu — white blood count; 
PLT — platelets; Hct — hematocrit
rd
3  day
nd
2  day
st
1  day
0.0%
0.0%
0.0%
0.0%
7.7%
7.7%
7.7%
46.6%
69.2%
53.8%
53.8%
38.5%
84.6%
53.8%
20.0% 40.0% 60.0% 80.0% 100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Ph < 7.35
Amylase > 108 U/L
CRP > 5 mg/L
9
Leu > 10 × 10 /L
9
PLT < 150 × 10 /L
Hct < 0.25
Table 4. Concomitant pharmacotherapy
Drug 1st day 2nd day 3rd day
Mean fluid intake [mL] 3707 3275 3695
Sedation (number of patients)
Midazolam 10 (76.9%) 9 (69.2%) 8 (61.5%)
Propofol 3 (23.1%) 4 (30.1%) 5 (38.5%)
Fentanyl 3 (23.1%) 9 (69.2%) 3 (23.1%)
Muscle relaxation (number of patients)
Rocuronium 7 (53.8%) 7 (53.8%) 7 (53.8%)
Pipecuronium 6 (46.1%) 6 (46.1%) 6 (46.1%)
Catecholamines (number of patients)
Dopamine 4 (30.1%) 3 (23.1%) 0
Dobutamine 1 (7.7%) 0 0
Norepinephrine 9 (69.2%) 9 (69.2%) 7 (53.8%)
No catecholamines 2 (15.4%) 2 (15.4%) 5 (38.5%)
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initial implementation of the procedure in our centre. The 
doubts were mostly associated with patients’ neurological 
status, with often more than 8 pts in GCS which reflected 
preserved reactions to external stimuli. Those patients, 
however, required administration of sedatives and muscle 
relaxants in order to optimize mechanical ventilation and 
perform invasive procedures or due to respiratory failure. 
Therefore, we may assume that in majority of cases in this 
group the use of MHT would not have prolonged the time 
of sedation and mechanical ventilation, but could have 
improved the prognosis.
Despite the inclusion criteria we decided to perform 
MTH in 2 patients after in-hospital cardiac arrest assuming 
that this treatment might have significantly improved their 
prognosis. MTH was implemented in young male who had 
multiple ventricular fibrillations during STEMI and after 
significantly prolonged CPR. As a result, a complete regain 
of consciousness without any neurological disorders was 
noted [18]. On the contrary, in case of a young woman 
who had no lesions in coronary arteries, MTH did not offer 
any benefit.
Despite MTH recognition as an improving prognosis 
treatment initially used external cooling methods caused 
difficulties and significantly limited the use of this pro-
cedure. Over the last few years novel devices have been 
introduced enabling to precisely control the body tempera-
ture by using intravascular cooling. In studies comparing 
different types of cooling this method has been regarded 
as significantly better due to easy management, possibil-
ity of setting and controlling the desired temperature and 
control of gradual re-warming process [19]. The use of 
intravascular cooling requires placement of catheter in the 
inferior vena cava via femoral vein. In our centre the pro-
cedure was performed shortly after coronary angiography 
or PCI and was not associated with any adverse event. No 
complications due to catheter implantation were observed. 
The management of the intravascular cooling device, tar-
get body temperature setting, its control and re-warming 
process were free of any adverse event. In one patient on 
the first day of cooling an adverse event occurred. It was 
an acute lower limb ischaemia associated with PCI that 
required MTH termination. In most of the studies the re-
searchers have emphasized the importance of correlation 
between MTH efficacy and time to its start from cardiac ar-
rest. The recommended method reducing time to initiation 
of proper cooling is intravenous infusion of cold saline [20, 
21]. However, there have been opinions recently question-
ing safety and efficacy of this type of treatment. Kim et al. 
[22] observed in randomized trial that patients who were 
given 2 litres of cold saline in the post-hospital period more 
often suffered from another cardiac arrest and pulmonary 
oedema and required higher doses of diuretics. In addition, 
faster reduction of body temperature to 34°C was not asso-
ciated with the improvement in the prognosis. In our centre 
we performed initial cooling with cold saline infusion but 
the amount of fluids was significantly lower (500–700 ml) 
than in Kim’s et al study. We did not observed any negative 
impact on hemodynamic state of patients. According to 
our observations those patients who survived had sooner 
been cooled with cold saline infusion and intravascular 
cooling device. In addition, due to lower body temperature 
prior to intravascular cooling, target body temperature was 
faster achieved in those patients. The data concerning 
correlation between time to ROSC and MTH effectiveness 
are controversial. There are some studies suggesting that 
MTH effectiveness is higher in patients with time to ROSC 
3–8 min and worse outcome is associated both with 
longer and shorter CPR time [23]. Other studies indicate 
inverse relationship with favorable impact on prognosis in 
hypothermia patients who had shorter time to ROSC [24].
In our study MTH patients who survived and were dis-
charged home had longer time to ROSC in comparison with 
patients who died. Data concerning time and course of CPR 
(gained from families or ambulance crew) are ambiguous 
and not precise and thus not always can be trustworthy. For 
this reason many scientists do not include this parameter 
in the analysis or substitute it with time from first medical 
contact [21].
In some studies patients’ higher body temperature on 
admission was associated with better MTH effectiveness 
[19]. In our study no such correlation was found.
In many articles MTH is said to have a favorable impact 
on late neurological status in patients after cardiac arrest 
[14, 25]. The time to regain consciousness in patients 
undergoing cooling is different. According to data it usu-
ally exceeds 3 days [26]. There have been reported cases 
of prolonged coma in patients after CPR who regained 
consciousness and had good neurological status [27]. 
MTH is said to alter the anoxic brain injury and prolong 
time to neurological improvement in patients with anoxic 
encephalopathy [16, 26]. The additional predictive factors 
of regaining consciousness and final neurological status 
are still unknown [26]. The correlation between time to 
regain consciousness and neurological status on discharge 
from hospital is regarded important by many authors but 
it still needs further investigations [26]. In our study time 
to regain consciousness was circa 7.2 days. Two patients 
who later regained consciousness died before discharge.
Last year there have been published some articles 
questioning the efficacy of MTH in patients after OHCA. 
In FINNRESUSCI study MTH effectiveness was confirmed 
in patients with ventricular fibrillation or ventricular tachy-
cardia requiring electrical cardioversion. No benefits were 
observed in patients with asystole or PEA [25]. An inten-
sive discussion started after publication of the results of 
a Nielsen’s et al study. This study showed no differences 
in mortality and neurological state in patients after OHCA 
cooled to 33°C in comparison with patients who had body 
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temperature of 36°C [28]. Some scientists claim this is 
an evidence for protective impact of antipyretic treatment 
in this group of patients [29]. Others emphasize long time 
from cardiac arrest to initiation of cooling (the inclusion 
time criteria: 4 h from cardiac arrest to randomization, 
and 4 h from randomization to target body temperature 
below 34°C) [30] and very fast re-warming process (6 h 
from 33°C to 36°C) [31] that could have had a negative 
impact on the prognosis. In addition, in the vast majority 
of patients recruited in this study cardiac arrest occurred 
in the presence of witnesses who immediately started 
CPR [32]. Currently, study of Nielsen et al. is not regarded 
as an adequate evidence in favor of terminating MHT in 
patients after OHCA.
Patients after out-of-hospital cardiac arrest due to 
STEMI have better prognosis than patients with other 
common diseases [21]. In addition, fast MHT implementa-
tion in patients with ACS, both STEMI and NSTEMI, helps 
to improve their neurological status but has no impact on 
30-day mortality rate [21, 33]. In presented group of pa-
tients after OHCA due to ACS treated with MTH there was 
a slight difference in mortality rate in comparison with pa-
tients with ACS with a standard treatment and other than 
ACS common disease. An objective comparison between 
those groups cannot be made due to different numbers 
of people in each group. Small difference in mortality 
in favor of patients treated with MTH may be caused by 
initial severe neurological state and poorer prognosis as 
a consequence. The results could have been influenced 
by the sample size which was not significant enough to 
draw statistical conclusions. Particular attention should 
be paid to the fact that almost all of our patients (5 out 
of 6) who survived to the discharge remained in good 
neurological condition. The data concerning adverse 
events in patients after cardiac arrest due to ACS, treated 
invasively and with MTH are controversial. There are stud-
ies suggesting more pronounced bleeding, thrombotic 
and infective complications in this group of patients [34, 
35]. In our study group we observed one case of acute 
stent thrombosis that happened shortly after hypother-
mia initiation. Acute lower limb ischaemia was noted in 
one patient suffering from lower limb atherosclerosis but 
the provocative factor could have been associated with 
femoral artery puncture. Infectious complications were 
the most common. Moreover, the diagnosis of infection 
in patients treated with MTH may pose serious problems 
due to difficulties in controlling body temperature. In 
addition, elevated CRP level and white blood count are 
also observed. Some of the noted adverse events such as 
bleeding or acute kidney failure could have been associa-
ted with therapeutic procedures (coronary angiography, 
PCI, dual antiplatelet therapy) but not with hypothermia.
Limitations of the study
No evaluation of statistically significant differences be-
tween patients who survived and who died was performed.
Conclusions
All the patients who survived and were treated with MTH 
were discharged in very good neurological status. The 
implementation of intravascular cooling device enables 
precise control of body temperature in patients undergoing 
the abovementioned procedure.
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Streszczenie
Wstęp. Łagodna hipotermia terapeutyczna (MTH) jest obiecującą metodą wspomagającą leczenie chorych po nagłym 
zatrzymaniu krążenia (NZK).
Materiał i metody. W latach 2012–2013 spośród kolejnych 216 chorych po NZK do MTH zakwalifikowano 13 pacjen-
tów. Schładzanie rozpoczynano w chwili przyjęcia wlewem dożylnym soli fizjologicznej o temperaturze 4°C, następnie 
kontynuowano hipotermię za pomocą zautomatyzowanego systemu wewnątrznaczyniowego. 
Wyniki. Badaną grupę stanowiło 5 kobiet i 8 mężczyzn (średni wiek 59 lat). Najczęstszym mechanizmem NZK były mi-
gotanie komór lub częstoskurcz komorowy w przebiegu zawału serca (92,3%). Średni czas do uzyskania spontanicznego 
krążenia (ROSC) wynosił 15 min 54 s, a od NZK do rozpoczęcia chłodzenia — 1 h 10 min. Podczas MTH obserwowano 
zwiększone leukocytozę, aktywności amylazy i stężenie CRP. W szpitalu zmarło 7 chorych (53,8%). Grupę pacjentów, 
którzy przeżyli, charakteryzowały: młodszy wiek (53,8 v. 63,6 roku), rzadszy wywiad choroby niedokrwiennej serca,
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częstsze występowanie migotania komór jako mechanizmu NZK, dłuższy czas do ROSC (mediana 19 v. 13 min), krótszy 
czas do rozpoczęcia wlewu zimnej soli fizjologicznej (mediana 58 v. 85 min), krótszy czas od NZK do rozpoczęcia chłodze-
nia śródnaczyniowego (mediana 3 h 20 min v. 3 h 50 min) oraz krótszy czas pobytu w szpitalu (mediana 471 v. 1232 h). 
Pięć osób wypisano ze szpitala w bardzo dobrym stanie neurologicznym (4 pacjentów — 0 pkt., 1 pacjent — 1 pkt w skali 
Rankina).
Wnioski. Wszyscy pacjenci, którzy przeżyli, a byli leczeni za pomocą MTH, zostali wypisani w bardzo dobrym stanie neu-
rologicznym. Stosowanie urządzenia do wewnątrznaczyniowego chłodzenia pozwala na precyzyjną kontrolę temperatury 
u pacjentów poddanych procedurze.
Słowa kluczowe: łagodna hipotermia terapeutyczna, nagłe zatrzymanie krążenia, ostry zespół wieńcowy
(Folia Cardiologica 2014; 9, 4: 327–336)
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